FDA Panel Weighs Grail's Galleri Test as Shares Are Halted

Trading in Grail (GRAL) was halted Wednesday while a Food and Drug Administration advisory committee met to discuss the company's Galleri multi-cancer blood screening test; the shares were last quoted at 108.55, up 0.54% on the day, as of 18:55 GMT on Sept. 23, 2026.

Trading in Grail (ticker: GRAL) was halted on Wednesday while a Food and Drug Administration advisory committee took up the company's blood-based cancer screening test, the event that will do more than anything else to define the company's commercial future. Before the halt, the stock was quoted at 108.55, up 0.54% on the day against a previous close of 107.97, with an intraday range running from 104.00 to 112.58, as of 18:55 GMT.

That range tells you most of what you need to know about how the market was handicapping the meeting. A swing of that width in a single session is not the behavior of a stock whose outcome is priced; it is the behavior of a stock where two very different futures are both still live, and traders are shuffling between them in real time until an exchange pulls the plug.

Why an advisory committee meeting stops the tape

Exchanges halt a stock when material information is about to reach the market unevenly. An FDA advisory committee meeting is close to the purest example: panelists speak in public, agency staff release briefing documents, and the tone of the discussion can shift a clinical-stage company's valuation within minutes. Halting trading lets everyone read the same transcript before the bidding resumes.

Advisory committees are made up of outside experts — clinicians, statisticians, patient representatives — who review the evidence and vote on questions the agency puts to them. Their conclusions are recommendations, not decisions. The FDA is not bound by them, and it has gone against panels in both directions. But in practice a panel's verdict is the single best public read on how the agency is thinking, and it reliably moves the stock of the company under review.

The specific question in front of a multi-cancer early detection test is unusually hard. Conventional screening tools are approved one disease at a time, against a well-defined comparator: does mammography find more breast cancers earlier than no mammography? A blood test that scans for signals from many cancers at once does not fit that template. Regulators have to weigh how many true cancers it catches, how many healthy people it sends into a cascade of imaging and biopsies, and whether finding a tumor earlier actually changes what happens to the patient.

What the panel review means for Grail's commercial path

Grail's Galleri test has been available in the United States through a laboratory pathway that does not require the same pre-market clearance as a marketed diagnostic device. Formal FDA authorization changes the economics rather than the availability. It is the gate to routine reimbursement — the difference between a test patients pay for out of pocket or through employers and one that insurers and public payers cover as a matter of course.

That distinction is the whole investment case. A screening test sold to self-payers and progressive corporate benefit plans has a ceiling measured in the low millions of people. A screening test folded into the standard adult check-up has a market measured against the entire eligible screening-age population. Nothing about the underlying science changes between those two worlds; the label does.

It also reshapes the cost side. Reimbursed volume brings scale to the sequencing and laboratory operations that sit behind each result, and unit economics in genomics improve sharply with throughput. Companies in this field have historically burned cash while waiting for exactly this kind of regulatory milestone, and the market prices them on the probability of reaching it rather than on current revenue.

Reading the price action around the halt

The pre-halt tape was volatile but not directionally decisive. At 108.55, the stock was up 0.54% on the day — a modest gain that conceals a session in which it traded as low as 104.00 and as high as 112.58. The market, in other words, could not settle on an answer while the meeting was still under way.

Context matters here. The broad market was soft on the day. The S&P 500 proxy SPY was at $767.97, down 0.70%; the Nasdaq 100 proxy QQQ was at $740.78, down 0.89%; and the Dow 30 proxy DIA sat at $514.55, off 0.67%, all as of 18:55 GMT. Against a tape where large-cap benchmarks were all lower, a small positive move in a single-catalyst biotech is a mild tell that the day's flow leaned constructive — but it is a weak signal, and one that a halt renders provisional.

Investors who have watched enough advisory committee meetings know the pattern that follows. The re-open is usually a gap rather than a glide, because the price has to absorb hours of information in one print. Positions that look reasonable at 108.55 can look very different at the first trade after the halt lifts, in either direction, and stop-loss orders provide little protection across a gap.

The wider bet on catching cancer earlier

The appeal of a single blood draw that screens for many cancers is obvious enough that it has drawn enormous capital into the sector. Most cancers have no screening program at all. For those, diagnosis typically comes after symptoms appear, by which point treatment options narrow and costs rise. A test that moves even a fraction of those diagnoses earlier has a public-health argument that is easy to state and difficult to prove.

Difficult, because proof requires showing not just detection but benefit — that people screened live longer or need less aggressive treatment than people who were not. That evidence takes years to accumulate, and regulators have been candid about the risk of over-diagnosis: finding indolent tumors that would never have harmed anyone, then treating them anyway.

Wednesday's meeting is where those competing arguments got aired in public. As Investor's Business Daily reported, the panel convened to discuss Grail's blood screening test while the stock sat halted.

What to watch after the halt lifts

Three things will matter more than the day's headline. First, the wording of the questions the FDA put to the panel — agencies signal their concerns through the questions they ask, and a narrowly framed question often foreshadows a narrowly framed label. Second, any discussion of which population a test would be authorized for; an age- or risk-restricted indication is a materially smaller market than a general adult screening indication. Third, the timeline to a formal agency decision, which follows the panel rather than accompanies it.

For shareholders, the practical point is that the advisory meeting is a waypoint, not a verdict. The stock will reprice on the panel's tone, then reprice again on the FDA's actual decision, and a third time on whatever payers decide to do about coverage. Each of those is a separate event with a separate set of risks, and each one is capable of moving a stock that has already shown it can travel more than eight points between its low and its high in a single session.

Key facts

• Stock: GRAL — 108.55, +0.54% on the day, as of 18:55 GMT Sept. 23, 2026
• Intraday range: 104.00 to 112.58; previous close 107.97
• Event: Trading halted Wednesday during an FDA advisory committee meeting on Grail's Galleri blood screening test
• Market backdrop: SPY $767.97 (-0.70%), QQQ $740.78 (-0.89%), DIA $514.55 (-0.67%)

Frequently asked questions

Why was Grail stock halted on Wednesday?

Trading in Grail was halted while a Food and Drug Administration advisory committee met to discuss the company's blood screening test for cancer. Exchanges halt stocks when material information is about to reach the market unevenly, and a public panel review of a company's lead product qualifies. The halt lets all participants read the same discussion before bidding resumes.

What did Grail shares do before the halt?

Grail was quoted at 108.55, up 0.54% from a previous close of 107.97, as of 18:55 GMT on Sept. 23, 2026. The session was volatile despite the small net change: the stock traded as low as 104.00 and as high as 112.58, a spread that shows the market had not settled on an outcome.

Is an FDA advisory committee recommendation binding?

No. Advisory committees are panels of outside experts — clinicians, statisticians and patient representatives — who review evidence and vote on questions the agency puts to them. Their conclusions are recommendations only. The FDA frequently follows them but is not required to, and has departed from panel votes in both directions in the past.

What is a multi-cancer early detection blood test?

It is a single blood draw designed to look for signals shed by many different cancers at once, rather than screening for one disease at a time. Most cancers currently have no routine screening program, so the appeal is catching disease before symptoms appear. The hard part is proving that earlier detection actually improves patient outcomes.

Why does FDA authorization matter if the test is already available?

Grail's test has been offered through a laboratory pathway that does not require the same pre-market clearance as a marketed device. Formal authorization mainly changes reimbursement: it is the gate to routine insurer and public-payer coverage, which converts a self-pay product with a limited customer base into one that can reach the broader screening-age population.

What should investors watch after the halt lifts?

The exact questions the FDA put to the panel, since agencies signal concerns through question wording; whether discussion pointed toward a restricted population rather than general adult screening; and the timeline to a formal agency decision, which comes after the panel. Re-opens following halts typically gap rather than glide, in either direction.

Sources

• The Holy Grail In Cancer? FDA Mulls New Blood Tests. — Investors Business Daily